Feature

New BP guidelines synergize with transformed primary care


 

Target:BP

Performance metrics are not the only path that could take U.S. medicine toward lower BP targets. Another active player is the Target:BP program, a voluntary quality-improvement program for increased U.S. hypertension awareness and better management launched in late 2015 as a collaboration between the AHA and the American Medical Association.

Given that both the new guideline and Target:BP were developed through partnerships involving the AHA, “it’s logical to connect [the guideline] to Target:BP, said Dr. Egan, an AHA spokesman for Target:BP and professor of medicine at the Medical University of South Carolina in Charleston.

Dr. Brent M. Egan, vice president for research at the Care Coordination Institute in Greenville, S.C., and professor of medicine at the Medical University of South Carolina in Charleston.

Dr. Brent M. Egan

Target:BP’s participants are health care organizations, including health systems, medical groups, community health centers, and physician practices. The program has two primary threads.

First, it functions as a recognition program that cites participating organizations if they achieve a prespecified level of BP control.

In 2017, the program released its initial list of successful participants, organizations that maintained at least 70% of their patients diagnosed with hypertension at a BP of less than 140/90 mm Hg. According to data reported by Willie E. Lawrence Jr., MD, during the AHA scientific sessions in November in Anaheim, Calif., 191 participating programs reached this level and won a “gold” designation from the program for their level of BP control during 2016, out of 310 participating organizations that submitted 2016 data to the program.

Pages

Recommended Reading

Higher preconception blood pressure linked to pregnancy loss
MDedge Internal Medicine
Distinguish neurogenic from nonneurogenic orthostatic hypotension
MDedge Internal Medicine
EAGLES: Smoking cessation therapy did not up cardiovascular risk
MDedge Internal Medicine
VIDEO: Triple-antihypertensive pill nails early therapy
MDedge Internal Medicine
MDedge Daily News: Diabetes patients ignore a deadly risk
MDedge Internal Medicine
Consider spironolactone in treatment-resistant hypertension
MDedge Internal Medicine
24-hour ambulatory BP measurements strongly predict mortality
MDedge Internal Medicine
Women’s representation in CV drug trials still lagging
MDedge Internal Medicine
Nebivolol looks like best beta-blocker for hypertension
MDedge Internal Medicine
MDedge Daily News: Is ‘medical aid in dying’ suicide?
MDedge Internal Medicine

Related Articles